244 related articles for article (PubMed ID: 35994385)
1. Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches.
Prasad S; Dimmock DP; Greenberg B; Walia JS; Sadhu C; Tavakkoli F; Lipshutz GS
Hum Gene Ther; 2022 Dec; 33(23-24):1228-1245. PubMed ID: 35994385
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.
Arjomandnejad M; Dasgupta I; Flotte TR; Keeler AM
BioDrugs; 2023 May; 37(3):311-329. PubMed ID: 36862289
[TBL] [Abstract][Full Text] [Related]
3. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
Verdera HC; Kuranda K; Mingozzi F
Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
[TBL] [Abstract][Full Text] [Related]
4. Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.
Hocquemiller M; Giersch L; Audrain M; Parker S; Cartier N
Hum Gene Ther; 2016 Jul; 27(7):478-96. PubMed ID: 27267688
[TBL] [Abstract][Full Text] [Related]
5. Evading the AAV Immune Response in Mucopolysaccharidoses.
Piechnik M; Sawamoto K; Ohnishi H; Kawamoto N; Ago Y; Tomatsu S
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32414007
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy of adeno-associated virus (AAV) vectors in preclinical models of ischemic stroke.
Wang J; Zhu M; Sun J; Feng L; Yang M; Sun B; Mao L
CNS Neurosci Ther; 2023 Dec; 29(12):3725-3740. PubMed ID: 37551863
[TBL] [Abstract][Full Text] [Related]
7. Infusion reactions to adeno-associated virus (AAV)-based gene therapy: Mechanisms, diagnostics, treatment and review of the literature.
Notarte KI; Catahay JA; Macasaet R; Liu J; Velasco JV; Peligro PJ; Vallo J; Goldrich N; Lahoti L; Zhou J; Henry BM
J Med Virol; 2023 Dec; 95(12):e29305. PubMed ID: 38116715
[TBL] [Abstract][Full Text] [Related]
8. An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission.
Suriano CM; Kumar N; Verpeut JL; Ma J; Jung C; Dunn CE; Carvajal BV; Nguyen AV; Boulanger LM
Mol Ther; 2024 Jun; 32(6):1721-1738. PubMed ID: 38566414
[TBL] [Abstract][Full Text] [Related]
9. Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders.
Marrone L; Marchi PM; Azzouz M
Expert Opin Biol Ther; 2022 Sep; 22(9):1163-1176. PubMed ID: 34904932
[TBL] [Abstract][Full Text] [Related]
10. Recent progress and considerations for AAV gene therapies targeting the central nervous system.
Lykken EA; Shyng C; Edwards RJ; Rozenberg A; Gray SJ
J Neurodev Disord; 2018 May; 10(1):16. PubMed ID: 29776328
[TBL] [Abstract][Full Text] [Related]
11. Delivery of Adeno-Associated Virus Vectors to the Central Nervous System for Correction of Single Gene Disorders.
Daci R; Flotte TR
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256124
[TBL] [Abstract][Full Text] [Related]
12. [Advancements in research on immune responses associated with adeno-associated virus vector-mediated ocular gene therapy].
Zhu XL; Zhang BN; Xie LX
Zhonghua Yan Ke Za Zhi; 2024 Mar; 60(3):289-295. PubMed ID: 38462380
[TBL] [Abstract][Full Text] [Related]
13. B cell focused transient immune suppression protocol for efficient AAV readministration to the liver.
Rana J; Herzog RW; Muñoz-Melero M; Yamada K; Kumar SRP; Lam AK; Markusic DM; Duan D; Terhorst C; Byrne BJ; Corti M; Biswas M
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101216. PubMed ID: 38440160
[TBL] [Abstract][Full Text] [Related]
14. Circumventing B Cell Responses to Allow for Redosing of Adeno-Associated Virus Vectors.
Ertl HCJ
Hum Gene Ther; 2023 Dec; ():. PubMed ID: 37861281
[TBL] [Abstract][Full Text] [Related]
15. Prednisolone and rapamycin reduce the plasma cell gene signature and may improve AAV gene therapy in cynomolgus macaques.
Kistner A; Chichester JA; Wang L; Calcedo R; Greig JA; Cardwell LN; Wright MC; Couthouis J; Sethi S; McIntosh BE; McKeever K; Wadsworth S; Wilson JM; Kakkis E; Sullivan BA
Gene Ther; 2024 Mar; 31(3-4):128-143. PubMed ID: 37833563
[TBL] [Abstract][Full Text] [Related]
16. Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials.
Wang Z; Tapscott SJ; Chamberlain JS; Storb R
Front Microbiol; 2011; 2():201. PubMed ID: 21980317
[TBL] [Abstract][Full Text] [Related]
17. Complement System Response to Adeno-Associated Virus Vector Gene Therapy.
Kropf E; Markusic DM; Majowicz A; Mingozzi F; Kuranda K
Hum Gene Ther; 2024 Mar; ():. PubMed ID: 38251650
[TBL] [Abstract][Full Text] [Related]
18. Planet of the AAVs: The Spinal Cord Injury Episode.
Stepankova K; Jendelova P; Machova Urdzikova L
Biomedicines; 2021 May; 9(6):. PubMed ID: 34071245
[TBL] [Abstract][Full Text] [Related]
19. Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside.
Ferreira V; Petry H; Salmon F
Front Immunol; 2014; 5():82. PubMed ID: 24624131
[TBL] [Abstract][Full Text] [Related]
20. The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution.
Kachanov A; Kostyusheva A; Brezgin S; Karandashov I; Ponomareva N; Tikhonov A; Lukashev A; Pokrovsky V; Zamyatnin AA; Parodi A; Chulanov V; Kostyushev D
Med Res Rev; 2024 Mar; ():. PubMed ID: 38549260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
